ARCHIVES

Gleevec Produces 59% Response Rate In Gastrointestinal Stromal Tumors

This article is from The Cancer Letter archive.

Vol. 24 No. 5 | May 25, 2001

Download PDF Visit The Full Archive

Related Articles

Cell Therapeutics To Appeal FDA Decision on Pixantrone.

September 17, 2010

1991 Bypass Budget Would Fund 50 Percent Of Competing Grants

May 26, 1989

Amgen, Genzyme, Thoratec Mourn Loss Of Executives Killed In Plane Hijackings.

September 21, 2001

Prostate Cancer Council Calls For Long-Term Screening Research

September 10, 1993

Benefit Seen In Novel Drug That Treats Gleevec Resistance

April 29, 2005

In Brief: Clinton Signs FY95 Apparitions Into Law, to Seek $12 Billion Recision; NIH CUTS Likely

October 29, 1993